9 days old

Health Economics & Outcomes Research Director (Xeljanz)

New York, NY 10007

To support the strategic goals of the Inflammation & Immunology (I&I) Business Unit (BU) by ensuring optimal reimbursement and access of Xeljanz. This role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance and robust evidence development to secure optimal global patient access and the value of our product. This role will serve as the HEOR Director to support product development, the launch and specifically the inline work for Xeljanz in UC.

The HEOR Director will function with a One PHI mindset and will work in a closely aligned fashion with leadership and PHI colleagues to ensure there is a single and coordinated view on strategy and delivery for PHI to the I&I business. The HEOR Director will partner with Global Product Development, Commercial Development, Global Medical, and other cross-functional teams to develop and implement health outcomes research strategies to support Xeljanz UC globally. Within PHI, the HEOR director will collaborate with country colleagues and the Centers of Excellence such as PCOA and RWDnA.


+ Lead the development of HEOR strategy to support the value of Xelajnz in close partnership with other PHI colleagues

+ Incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence in line with overall medical strategy for the assets and to ensure global reimbursement and access requirements. Provide strategic input in the selection of relevant patient population and comparators within clinical trials to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.

+ Development and validation of new Patient Reported Outcomes measures as appropriate for inclusion across clinical trials, registries, and prospective real world studies.

+ Lead the execution of HEOR studies and projects (including Non-Interventional Studies, registries, etc.) in alignment with the global HEOR strategy and demonstrate the value proposition for Xeljanz in UC.

+ Identify opportunities to partner with I&I BU external customers to conduct HEOR projects in support of asset strategies

+ Lead the timely development of deliverables including global value dossiers (GVDs), evidence blueprints, economic models, and innovative tools to successfully support global launch, reimbursement and access requirements in conjunction with the regions/countries.

+ Lead the coordination of input from local country/regional HEOR teams on evidence needs and ensure that the input is appropriately incorporated to develop and integrated evidence strategy to support global market access needs at time of launch.

+ Develop real world evidence generation strategies and flawlessly execute studies (e.g., burden of illness studies, epidemiology studies, etc).

+ Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, and various academic and community settings to support asset strategies.

+ Collaborate with local health and value affiliates and enable local model adaptations and updates throughout the product life cycle.

+ Provide strategic guidance and content guidance in reimbursement (re)negotiations for Pfizer products.

+ Lead the development of appropriate data dissemination plans and communicate evidence generated via publications and conference presentations.

**Basic Qualifications**

+ Minimum Masters degree (MSc, MPH) in health services research, public health, epidemiology, or health economics

+ Minimum 8 years' experience in health outcomes and related fields, 5 of which are as part of global health economics and/or outcomes research teams in a pharmaceutical company or in consultancy space

+ **Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.**

**Preferred Qualifications**

+ Doctoral degree (PhD, DrPH, ScD) in health services research, public health, epidemiology, or health economics

+ Strong working knowledge of the technical and methodological aspects of registries and observational study design and implementation. Capable of independently managing complex registry and non-interventional study projects.

+ Strong methodological skills (study design, data analysis and interpretation) in clinical trials, epidemiology, or health services research is required

+ In depth understanding of Pharmacoeconomics and Health-related Quality of Life

+ Knowledge and experience in the I&I therapeutic area is preferred

+ Experience with HTA organizations such as NICE, SMC, PBAC is expected

+ Experience with US Health Care System desirable

+ Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers

+ Excellent oral and written English communication skills required

+ Strong project management abilities (contracting, budgeting, vendor management) essential. Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities

+ Ability to influence key members of medical and commercial teams constructively and without conflict

+ Skilled in functioning within a matrix organization where managing through influence is required

**Sunshine Act**

Pfizer reports payments and other transfers of value to health care providers as required by federal and state transparency laws and implementing regulations. These laws and regulations require Pfizer to provide government agencies with information such as a health care provider's name, address and the type of payments or other value received, generally for public disclosure. Subject to further legal review and statutory or regulatory clarification, which Pfizer intends to pursue, reimbursement of recruiting expenses for licensed physicians may constitute a reportable transfer of value under the federal transparency law commonly known as the Sunshine Act. Therefore, if you are a licensed physician who incurs recruiting expenses as a result of interviewing with Pfizer that we pay or reimburse, your name, address and the amount of payments made currently will be reported to the government. If you have questions regarding this matter, please do not hesitate to contact your Talent Acquisition representative.

**EEO & Employment Eligibility**

Pfizer is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Pfizer also complies with all applicable national, state and local laws governing nondiscrimination in employment as well as work authorization and employment eligibility verification requirements of the Immigration and Nationality Act and IRCA. Pfizer is an E-Verify employer.

**Last Date to Apply for Job: November 22, 2019**

Eligible for Employee Referral Bonus


Pfizer is an equal opportunity employer and complies with all applicable equal employment opportunity legislation in each jurisdiction in which it operates.

Market Access


Posted: 2019-11-08 Expires: 2019-12-08

Before you go...

Our free job seeker tools include alerts for new jobs, saving your favorites, optimized job matching, and more! Just enter your email below.

Share this job:

Health Economics & Outcomes Research Director (Xeljanz)

New York, NY 10007

Join us to start saving your Favorite Jobs!

Sign In Create Account
Powered ByCareerCast